Overview

Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer

Status:
Active, not recruiting

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This phase II trial studies how well inolitazone dihydrochloride (efatutazone dihydrochloride) and paclitaxel work in treating patients with anaplastic thyroid cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Drugs used in chemotherapy, such as efatutazone dihydrochloride and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Phase:

Phase 2

Details

Lead Sponsor:

Alliance for Clinical Trials in Oncology

Collaborators:

Daiichi Sankyo Inc.
Daiichi Sankyo, Inc.
National Cancer Institute (NCI)

Treatments:

Albumin-Bound Paclitaxel
Efatutazone
Paclitaxel